Skip to content
Review Open access

From first seizure to specific antiseizure medication in Dravet syndrome: Quantifying delays in the DS'coverED study

Aug 2026 · Epilepsia Open · 0 citations · 62 references
Medicine

TL;DR

The DS'coverED European survey explored each step of the diagnostic journey and identified residual barriers and opportunities to optimize the time to diagnosis and access to Dravet syndrome‐specific antiseizure medications.

Abstract

Abstract Objective Dravet syndrome (DS) is a rare early‐onset developmental and epileptic encephalopathy with persistent delays between seizure onset and diagnosis. The DS'coverED study aimed to characterize current diagnostic timelines by examining each step and its duration, identifying residual barriers, and actionable solutions to optimize the diagnostic process within real‐world clinical pathways. Methods A steering committee—eight pediatric neurologists and one representative from the DS European Federation—developed a survey addressed to European pediatric neurologists experienced in DS management. Responders reported information on their medical practice and data on patients' diagnostic pathways from seizure onset to initiation of DS‐specific antiseizure medications (ASMs). Results Fifty‐three physicians participated in the study. Analysis of 45 patient diagnostic pathways revealed marked heterogeneity in the DS diagnostic pathway. The median age at formal diagnosis was 15 months, with a median interval of 11 months between seizure onset and diagnosis. While half of the patients received a diagnosis within 1 year of seizure onset, 25% were diagnosed after 23 months of age. Diagnostic delays were primarily associated with late referral to expert centers and prolonged access or turnaround times for genetic testing. Although 45% of responders requested genetic testing promptly after initial consultation, more than half waited for confirmatory results before formally communicating the diagnosis. Initiation of DS‐specific ASMs was inconsistent—occurring a median of 3 months after diagnosis but exceeding 9 months in 27% of cases—likely influenced by clinician caution, drug availability, and parental concerns regarding the treatment regimen. Significance DS'coverED seeks to fill a critical knowledge gap in the DS diagnostic pathway. The study provides healthcare professionals with benchmarks for refining their diagnostic practices and guiding clinical improvements—ongoing clinician education, better healthcare system coordination, and active caregiver engagement. Plain Language Summary The diagnosis of Dravet syndrome, a rare and severe form of childhood epilepsy, is still often delayed after the first seizure. The DS'coverED European survey explored each step of the diagnostic journey and identified residual barriers and opportunities to optimize the time to diagnosis and access to Dravet syndrome‐specific antiseizure medications. It provides physicians with actionable solutions that can help improve the diagnostic process of the condition.

Read PDF

Similar papers

Open access Sep 2026

Dravet Syndrome: A Primer for Behavior Analysts

An introduction to the complex and unique characteristics of DS is provided for those working in the field of behavior analysis with the hope of facilitating innovative research to discover effective applied behavior analytic interventions and treatments to help individuals with DS receive the needed supports and live...

Isabel B. Hayes, Kasey E. Bedard, A. Ulm et al. · 0 citations
Open access Aug 2026

Pediatric developmental epileptic encephalopathies treated with cenobamate: Real-world outcomes across etiologies, syndromes, and seizure types.

CNB was associated with sustained effectiveness and acceptable tolerability across pediatric DEEs and slow weight-based titration and proactive simplification of sodium channel blockers and clobazam may optimize benefit-risk.

Á. Aledo-Serrano, Adrián Valls-Carbó, E. González-Alguacil et al. · 0 citations
Open access Sep 2026

Treatment responses to antiseizure medication in children with Angelman syndrome.

BACKGROUND Angelman Syndrome (AS) is a rare neurodevelopmental disorder with epilepsy affecting up to 90% of the children. Although several studies have examined antiseizure medications (ASMs) in children with AS, preferred ASMs vary between countries and while new ASMs have become available in clinical practice in rec...

L. Manssen, Patrick Pfarrer, J. Gburek-Augustat et al. · 0 citations
Sep 2026

Functional (dissociative) seizures in PCDH19-clustering epilepsy: Clinical characteristics and diagnostic challenges.

OBJECTIVE Functional (dissociative) seizures (FDS) are increasingly recognized among individuals with epilepsy, intellectual disability (ID), and psychiatric disorders, but their occurrence in PCDH19-clustering epilepsy (CE) has not been systematically described. We aimed to characterize the clinical features, diagnost...

Rita Cagigal, J. Peña-Ceballos, Patrick B. Moloney et al. · 0 citations
Review Open access Oct 2026

Pediatric new-onset seizure-like events: Yield of diagnostic work-up.

In children with an initially undefined diagnosis, repeated EEG recordings, particularly sleep-deprived EEG, contribute to a final epilepsy diagnosis more frequently than MRI or genetic testing.

G. Slinger, Lotte Noorlag, W. Otte et al. · 0 citations
Review Oct 2026

Diagnosing Lennox-Gastaut syndrome in adulthood: A scoping review of diagnostic challenges and age-related electroclinical evolution.

OBJECTIVE Lennox-Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy typically diagnosed in childhood. The 2022 International League Against Epilepsy (ILAE) criteria provide a diagnostic framework built on pediatric data, but their applicability in adulthood is challenged by disease evolution, treatm...

C. Liguori, S. Casciato, Emanuele Cerulli Irelli et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.